WG
TPST icon

Winton Group’s Tempest Therapeutics TPST Stock Holding History

Winton Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-479
Closed -$112K – 1515
2021
Q1 		$112K Buy
479
+91
+23% +$36.8K 0.01% 1328
2020
Q4 		$162K Sell
388
-547
-59% -$189K 0.01% 1223
2020
Q3 		$297K Buy
+935
New +$317K 0.01% 1253

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Winton Group's TPST Position: Q2 2021 in Review

Winton Group sold out of Tempest Therapeutics (TPST) in Q2 2021, closing a stake of 479 shares — an estimated $112K sold.

Winton Group first reported a position in TPST in Q3 2020 and held it in 3 quarters. The position peaked at $297K in Q3 2020. 23 funds tracked by Wall St. Rank hold TPST as of Q2 2021.

  • Winton Group reported no remaining Tempest Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Winton Group sold 479 Tempest Therapeutics shares in Q2 2021, an estimated $112K.
  • Winton Group first reported a position in Tempest Therapeutics in Q3 2020 and held it in 3 quarters.
  • Winton Group's Tempest Therapeutics position peaked at $297K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2021.

Based on Winton Group's 13F filing for Q2 2021, filed 10 Aug 2021.